90 filings
8-K
VKTX
Viking Therapeutics Inc
24 Apr 24
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:05pm
8-K
VKTX
Viking Therapeutics Inc
26 Mar 24
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
7:08am
8-K
VKTX
Viking Therapeutics Inc
4 Mar 24
Other Events
4:52pm
8-K
VKTX
Viking Therapeutics Inc
1 Mar 24
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
4:05pm
8-K
VKTX
Viking Therapeutics Inc
27 Feb 24
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
7:04am
8-K
r0gbpv
7 Feb 24
Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
73qyw4a9ovanxyzpunb
25 Oct 23
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:24pm
8-K
aicczplly5f4g8 3ciyz
26 Jul 23
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
8-K
f3caj2
14 Jun 23
Submission of Matters to a Vote of Security Holders
4:23pm
8-K
pgu7qhip8
11 May 23
Amendments to Articles of Incorporation or Bylaws
5:00pm
8-K
qtsb2n737au3c2
26 Apr 23
Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:06pm
8-K
ie0ixw
3 Apr 23
Viking Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Underwriters’ Option to Purchase Additional Shares
5:17pm
8-K
jy5zi4dxsd44q32
31 Mar 23
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
5:27pm
8-K
rb4txfok1g7spm
28 Mar 23
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
7:10am
8-K
wydcox
28 Mar 23
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735
6:42am
8-K
t5l tjxxko
8 Feb 23
Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
4:10pm
8-K
z5huxnsb2ixuaogiyg6
26 Oct 22
Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:32pm
8-K
qovlvtglftn76096fn
27 Jul 22
Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:11pm
8-K
3ghhe
26 May 22
Submission of Matters to a Vote of Security Holders
4:10pm
8-K
abpvcgd4 fo25qvr80x
27 Apr 22
Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:44pm